AVL-292

Brand

No Brand

Description

AVL-292 is an orally available and highly selective covalent inhibitor of Bruton’s tyrosine kinase (Btk) that is currently undergoing Phase 1b clinical development for CLL and B-NHL. AVL-292 selectively and covalently bonds to Btk to inactivate and silence its activity. AVL-292 inhibited osteoclast function and reduced osteoclast-stimulated proliferation of MM cells. AVL-292 was well tolerated from 125-400 mg po QD and early efficacy analysis in CLL and B-NHL shows 10/11 efficacy evaluable pts with SD. The ongoing phase Ib clinical trial of AVL-292 is being conducted in patients with B-cell malignancies, including B-cell NHL, CLL, and WM.

Application

Reactivity

Photos